(-0.14%) 5 205.50 points
(-0.17%) 39 127 points
(-0.17%) 18 155 points
(0.70%) $79.54
(-1.33%) $2.16
(0.03%) $2 322.90
(1.25%) $27.95
(0.55%) $990.00
(0.18%) $0.932
(0.27%) $10.92
(0.13%) $0.801
(0.01%) $91.75
Live Chart Being Loaded With Signals
Glenmark Life Sciences Limited develops, manufactures, and supplies non-commoditized active pharmaceutical ingredients for various chronic therapeutic areas in India...
Stats | |
---|---|
Today's Volume | 72 732.00 |
Average Volume | 138 777 |
Market Cap | 102.11B |
EPS | INR9.69 ( 2023-10-20 ) |
Last Dividend | INR21.00 ( 2023-03-24 ) |
Next Dividend | INR0 ( N/A ) |
P/E | 21.73 |
ATR14 | INR1.741 (0.21%) |
Volume Correlation
Glenmark Life Sciences Correlation
10 Most Positive Correlations | |
---|---|
APCOTEXIND.NS | 0.907 |
AMIORG.NS | 0.849 |
RAMKY.NS | 0.83 |
RAMRAT.NS | 0.814 |
MAXVIL.NS | 0.811 |
GMRINFRA.NS | 0.801 |
10 Most Negative Correlations | |
---|---|
LTGILTBEES.NS | -0.87 |
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Glenmark Life Sciences Correlation - Currency/Commodity
Glenmark Life Sciences Financials
Annual | 2023 |
Revenue: | INR22.83B |
Gross Profit: | INR12.81B (56.11 %) |
EPS: | INR38.43 |
FY | 2023 |
Revenue: | INR22.83B |
Gross Profit: | INR12.81B (56.11 %) |
EPS: | INR38.43 |
FY | 2022 |
Revenue: | INR21.61B |
Gross Profit: | INR11.47B (53.08 %) |
EPS: | INR38.11 |
FY | 2022 |
Revenue: | INR21.23B |
Gross Profit: | INR10.80B (50.88 %) |
EPS: | INR35.63 |
Financial Reports:
No articles found.
Glenmark Life Sciences Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
INR10.50 (N/A) |
INR0 (N/A) |
INR21.00 (N/A) |
INR0 (N/A) |
INR0 (N/A) |
INR0 (N/A) |
INR0 (N/A) |
INR0 (N/A) |
INR0 (N/A) |
INR0 (N/A) |
Very Unsafe
High risk of being cut
Unsafe
Heightened risk of being cut
Borderline
Moderate risk of being cut
Safe
Unlikely to be cut
Very Safe
Very unlikely to be cut
First Dividend | INR10.50 | 2021-11-22 |
Last Dividend | INR21.00 | 2023-03-24 |
Next Dividend | INR0 | N/A |
Payout Date | 0000-00-00 | |
Next Payout Date | N/A | |
# dividends | 3 | -- |
Total Paid Out | INR42.00 | -- |
Avg. Dividend % Per Year | 1.99% | -- |
Score | 4.06 | -- |
Div. Sustainability Score | 10.00 | |
Div.Growth Potential Score | 5.62 | |
Div. Directional Score | 9.11 | -- |
Year | Amount | Yield |
---|---|---|
2021 | INR10.50 | 1.40% |
2022 | INR10.50 | 1.68% |
2023 | INR21.00 | 5.03% |
2024 | INR0 | 0.00% |
The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. However, its Dividend Growth Potential Score (DGPS) is only moderate, indicating limited growth potential. In summary, the company provides a promising overall dividend outlook, balancing both sustainability and growth potential.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
SOBHA.NS | Dividend Junior | 2023-07-28 | Annually | 18 | 0.43% | |
MINDTECK.NS | Dividend Junior | 2023-08-04 | Sporadic | 8 | 0.28% | |
HBSL.NS | Dividend Junior | 2023-08-11 | Sporadic | 12 | 0.78% | |
BEPL.NS | Dividend King | 2023-07-25 | Semi-Annually | 20 | 4.91% | |
RAILTEL.NS | Dividend Junior | 2023-08-24 | Semi-Annually | 4 | 1.19% | |
KHAICHEM.NS | No Dividend Player | 2023-07-21 | Annually | 5 | 0.32% | |
EMAMIPAP.NS | Dividend Junior | 2023-09-05 | Annually | 3 | 0.56% | |
AJANTPHARM.NS | Dividend Knight | 2023-08-04 | Annually | 23 | 0.57% | |
SUPRAJIT.NS | Dividend Junior | 2023-09-18 | Semi-Annually | 20 | 0.45% | |
NAVNETEDUL.NS | Dividend Junior | 2023-08-07 | Annually | 22 | 1.10% |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | 0.206 | 1.500 | 5.88 | 8.81 | [0 - 0.5] |
returnOnAssetsTTM | 0.165 | 1.200 | 4.49 | 5.39 | [0 - 0.3] |
returnOnEquityTTM | 0.204 | 1.500 | 8.85 | 10.00 | [0.1 - 1] |
payoutRatioTTM | 0 | -1.000 | 0 | 0 | [0 - 1] |
currentRatioTTM | 4.37 | 0.800 | 10.00 | 8.00 | [1 - 3] |
quickRatioTTM | 2.64 | 0.800 | 10.00 | 8.00 | [0.8 - 2.5] |
cashRatioTTM | 0.687 | 1.500 | 7.29 | 10.00 | [0.2 - 2] |
debtRatioTTM | 0.00602 | -1.500 | 9.90 | -10.00 | [0 - 0.6] |
interestCoverageTTM | 408.14 | 1.000 | 10.00 | 10.00 | [3 - 30] |
operatingCashFlowPerShareTTM | 6.33 | 2.00 | 7.89 | 10.00 | [0 - 30] |
freeCashFlowPerShareTTM | 6.33 | 2.00 | 6.83 | 10.00 | [0 - 20] |
debtEquityRatioTTM | 0.00735 | -1.500 | 9.97 | -10.00 | [0 - 2.5] |
grossProfitMarginTTM | 0.561 | 1.000 | 3.98 | 3.98 | [0.2 - 0.8] |
operatingProfitMarginTTM | 0.276 | 1.000 | 6.47 | 6.47 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | 4.54 | 1.000 | 10.00 | 10.00 | [0.2 - 2] |
assetTurnoverTTM | 0.801 | 0.800 | 7.99 | 6.39 | [0.5 - 2] |
Total Score | 12.61 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | 21.92 | 1.000 | 7.89 | 0 | [1 - 100] |
returnOnEquityTTM | 0.204 | 2.50 | 9.26 | 10.00 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | 6.33 | 2.00 | 7.89 | 10.00 | [0 - 30] |
dividendYielPercentageTTM | 2.68 | 1.500 | 10.00 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | 6.33 | 2.00 | 7.89 | 10.00 | [0 - 30] |
payoutRatioTTM | 0 | 1.500 | 0 | 0 | [0 - 1] |
pegRatioTTM | 2.37 | 1.500 | 10.00 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | 0.0341 | 1.000 | -1.648 | 0 | [0.1 - 0.5] |
Total Score | 5.62 |
Glenmark Life Sciences
Glenmark Life Sciences Limited develops, manufactures, and supplies non-commoditized active pharmaceutical ingredients for various chronic therapeutic areas in India. The company offers Olmesartan, Amiodarone, Telmisartan, Perindopril, Rosuvastatin, and Cilostazol for cardiovascular diseases; Oxcarbazepine, Zonisamide, Topiramate, Bupropion, Ropinirole, Riluzole, and Lacosamide for central nervous system diseases; Glimepiride, Teneligliptin, Vildagliptin, and Linagliptin for diabetes; and Etoricoxib and Lornoxicam for pain management. It also provides Atovaquone, Voriconazole, Mirabegron, Desloratadine, Esomeprazole Magnesium, Adapalene, and Fluconazole gastro-intestinal disorders, anti-infective, respiratory, anti-emetic, and other therapeutic areas. In addition, the company offers contract development and manufacturing services to a range of multinational pharmaceutical and specialty pharmaceutical companies. It also exports its products to Europe, North America, Latin America, Japan, and internationally. The company was incorporated in 2011 and is based in Mumbai, India. Glenmark Life Sciences Limited is a subsidiary of Glenmark Pharmaceuticals Limited.
About Live Signals
The live signals presented on this page help determine when to BUY or SELL NA. The signals have upwards of a 1-minute delay; like all market signals, there is a chance for error or mistakes.
The live trading signals are not definite, and getagraph.com hold no responsibility for any action taken upon these signals, as described in the Terms of Use. The signals are based on a wide range of technical analysis indicators